Breo Ellipta vs Daliresp
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Breo Ellipta | US Daliresp | |
|---|---|---|
| Generic name | fluticasone/vilanterol | roflumilast |
| Drug class | ICS/LABA Inhaler | PDE4 Inhibitor (Oral) |
| Treats | Asthma, COPD | Chronic obstructive pulmonary disease (COPD) |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | AstraZeneca |
| Year approved | 2013 | 2011 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $100M | — |
| Common side effects | Oral thrush, Throat irritation, Headache, Common cold symptoms | Diarrhea, Weight loss, Nausea, Headache |
Breo Ellipta
Frequently asked questions
Is Breo Ellipta or Daliresp better?
Neither is universally "better." Breo Ellipta (fluticasone/vilanterol) and Daliresp (roflumilast) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Breo Ellipta and Daliresp?
Breo Ellipta is a ICS/LABA Inhaler made by GSK, while Daliresp is a PDE4 Inhibitor (Oral) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Breo Ellipta has the larger estimated TV advertising budget of the two.